Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BUB1 | O43683 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.33 |
| ▸ | RORC | P51449 | 2/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1293778 | 1.00 | BUB1 (0.35) | BUB1CHRM2CHRM1CHRM3GPR119 | |
| SCHEMBL631011 | 1.00 | BUB1 (0.35) | BUB1CHRM2CHRM1CHRM3GPR119 | |
| SCHEMBL6783662 | 0.91 | BUB1 (0.34) | BUB1CHRM2CHRM1CHRM3GPR119 | |
| SCHEMBL1293777 | 0.88 | BUB1 (0.35) | BUB1CHRM2CHRM1CHRM3RORC | |
| SCHEMBL4767608 | 0.88 | BUB1 (0.35) | BUB1CHRM2CHRM1CHRM3RORC | |
| SCHEMBL17483741 | 0.85 | BUB1 (0.34) | BUB1CHRM2CHRM1CHRM3DDB1 | |
| SCHEMBL3010410 | 0.85 | BUB1 (0.34) | BUB1CHRM2CHRM1CHRM3DDB1 | |
| SCHEMBL3010408 | 0.85 | BUB1 (0.34) | BUB1CHRM2CHRM1CHRM3DDB1 | |
| SCHEMBL3658980 | 0.82 | BUB1 (0.38) | BUB1CHRM2CHRM1CHRM3DDB1 | |
| SCHEMBL18047737 | 0.79 | GPR119 (0.32) | BUB1GPR119RORCUSP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119183453-A | STAT modulators and uses thereof | 瑞克鲁迪克斯制药股份有限公司 | 2024-12-24 | — | — | CN | disclosed |
| WO-2024123102-A1 | NOVEL TRICYCLIC COMPOUND AS KRAS G12D INHIBITOR, AND USE THEREOF | 에스케이바이오팜 주식회사 | 2024-06-13 | — | — | WO | disclosed |
| WO-2023109471-A1 | SPIRO PYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 上海赛默罗生物科技有限公司 | 2023-06-22 | — | — | WO | disclosed |
| CN-114026066-A | Process for preparing alpha-carboxamide pyrrolidine derivatives | 生物基因麻省公司 | 2022-02-08 | — | — | CN | disclosed |
| EP-2945939-B1 | THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE HOLDINGS CORP (US) | 2020-03-04 | — | — | EP | disclosed |
| EP-2499127-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-09-05 | — | — | EP | disclosed |
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| US-9776981-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-03 | — | — | US | disclosed |
| EP-2499115-B1 | PROCESS FOR PREPARING HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB HOLDINGS IRELAND (CH) | 2016-07-27 | — | — | EP | disclosed |
| US-9303007-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-04-05 | — | — | US | disclosed |
| WO-2008090116-A1 | NOVEL PHARMACEUTICAL COMPOSITIONS | GLAXO GROUP LIMITED (GB) | 2008-07-31 | — | — | WO | disclosed |
| WO-2008090114-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 2-METHOXY-5- (5-TRIFLUOROMETHYL-TETRAZOL-I-YL-BENZYL) - (2S-PHENYL-PIPERIDIN-3S-YL-) | GLAXO GROUP LIMITED (GB) | 2008-07-31 | — | — | WO | disclosed |
| WO-2008090117-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 3, 5-DIAMIN0-6- (2, 3-DICHL0PHENYL) -L, 2, 4-TRIAZINE OR R (-) -2, 4-DIAMINO-5- (2, 3-DICHLOROPHENYL) -6-FLUOROMETHYL PYRIMIDINE AND AN NK1 | GLAXO GROUP LIMITED (GB) | 2008-07-31 | — | — | WO | disclosed |
| WO-2008090115-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NK1 RECEPTOR ANTAGONISTS AND SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2008-07-31 | — | — | WO | disclosed |
| EP-1943216-A1 | PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | GLAXO GROUP LIMITED (GB) | 2008-07-16 | — | — | EP | disclosed |
| EP-1934176-A1 | QUATERNARY ALPHA-AMINOCARBOXAMIDE DERIVATIVES AS MODULATORS OF VOLTAGE-GATED SODIUM CHANNELS | GLAXO GROUP LIMITED (GB) | 2008-06-25 | — | — | EP | disclosed |
| EP-1934177-A1 | PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | GLAXO GROUP LIMITED (GB) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007042239-A1 | PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | GLAXO GROUP LIMITED (GB) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007042240-A1 | QUATERNARY ALPHA-AMINOCARBOXAMIDE DERIVATIVES AS MODULATORS OF VOLTAGE-GATED SODIUM CHANNELS | GLAXO GROUP LIMITED (GB) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007042250-A1 | PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | GLAXO GROUP LIMITED (GB) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | HAVCR2, LIPC, PYGL | BUB1 2339/4885CHRM2 4738/4885CHRM1 4748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.